ArticleScientific reports2023
Point-of-care testing with Xpert HPV for single-visit, screen-and-treat for cervical cancer prevention: a demonstration study in South Africa.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Individual-level HPV vaccination verification in Botswana: lessons learned from implementation of the HOPE II trial.Frontiers in public health · 2026Trial
- Delivering cervical cancer screening and management to women in remote communities of the Peruvian Amazon: a mixed methods analysis of a mobile point-of-care intervention.Lancet regional health. Americas · 2026Article
- Mock Samples That Mimic Human Cervicovaginal Samples to Accelerate the Development and Evaluation of Assays for High-Risk HPV for Cervical Cancer Screening.Journal of medical virology · 2026Article
- Advancing the elimination of cervical cancer across Africa.Nature communications · 2026Review
- Cervical Cancer Screening in Women Living with HIV in South Africa: Addressing Health Disparities Through Integrated Prevention Strategies.International journal of women's health · 2026Review
- Screen-and-treat: a sustainable solution for cervical cancer elimination in low and middle income countries.BMJ oncology · 2026Review
- Performance of thermoablation among women treated for high-risk human papillomavirus in a screen-and-treat program in South Africa.International journal of cancer · 2025Article
- Article
- Improved cervical screening using HPV type restriction and cycle threshold limit setting with the AmpFire assay: A prospective screening cohort of women with and without HIV in Botswana.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- Age-period-cohort analysis of global, regional, and national cervical cancer prevalence trends in women of childbearing age (15-49 years), 1990-2021.BMC women's health · 2025Article
- First Decade of the National Cancer Institute's Affordable Cancer Technologies Program: Accelerating Translational Technology Research and Development for Cancer Globally.JCO global oncology · 2025Review
- A randomised controlled non-inferiority trial to compare the efficacy of 'HPV screen, triage and treat' with 'HPV screen and treat' approach for cervical cancer prevention among women living with HIV.Nature communications · 2025Article
- Accuracy of POC testing systems for HPV screening: the importance of disease prevalence and characteristics of the screened population.Infectious agents and cancer · 2024Article
- Natural History of High-Risk Human Papillomavirus in Kenyan and South African Women: Implications for Vaccination Campaigns and Cervical Cancer Screening Programs.Open forum infectious diseases · 2024Article
- A cervical cancer control strategy for lower-resource settings: interventions to complement one-dose HPV vaccination.Journal of the National Cancer Institute. Monographs · 2024Article
- Persistent human papillomavirus after thermal ablation in Malawian women with and without HIV: Implications for risk-based cervical cancer prevention in low- and middle-income countries.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Human papillomavirus (HPV)-based screen-and-treat (SAT) is recommended but implementation presents operational challenges. We implemented HPV-SAT at a research site in Khayelitsha, South Africa, screening 3062 women aged 30-65 years (44% women living with HIV [WHIV]). All were screened using point-of-care Xpert HPV and almost all received their HPV results on the same day. HPV-positivity occurred in 41.5% of WHIV and 17.4% of women without HIV (WNoH) reducing to 26.2% in WHIV and 10.4% in WNoH applying treatment eligibility criteria based on high viral load in the channels detecting HPV16, 18, 45, 16, 18, 31, 33, 35, 52, 58. Among those eligible for treatment, 91.3% were considered suitable for ablative therapy, and 94.6% underwent thermal ablation on the same day, with no serious adverse events. Twelve months later, 39.0% of WHIV and 65.2% of WNoH treated with ablative therapy were clear of HPV. In women who were HPV-positive but ineligible for treatment, 19.1% and 12.9% had histologically-confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2+) at 12 months. SAT programs need to weigh trade-offs between overtreatment versus delayed or no treatment for women who test positive for HPV. Treatment modalities for precancerous lesions need to be improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.